Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153428 | 0.86 | CHRM1 (0.33) | CHRM1CHRM4 | |
| SCHEMBL15618693 | 0.83 | CHRM4 (0.53) | CHRM1CHRM4CHRM2ALDH1A1L3MBTL1 | |
| SCHEMBL15618604 | 0.82 | CHRM4 (0.50) | CHRM1CHRM4CHRM2ALDH1A1L3MBTL1 | |
| SCHEMBL17005037 | 0.82 | CHRM1 (0.69) | CHRM1CHRM4CHRM2ALDH1A1L3MBTL1 | |
| SCHEMBL15618708 | 0.82 | CHRM1 (0.69) | CHRM1CHRM4CHRM2ALDH1A1L3MBTL1 | |
| SCHEMBL17014924 | 0.82 | CHRM4 (0.49) | CHRM1CHRM4CHRM2ALDH1A1L3MBTL1 | |
| SCHEMBL16217929 | 0.81 | CHRM1 (0.70) | CHRM1CHRM4CHRM2ALDH1A1L3MBTL1 | |
| SCHEMBL15630224 | 0.80 | CHRM4 (0.48) | CHRM1CHRM4CHRM2ALDH1A1L3MBTL1 | |
| SCHEMBL20585575 | 0.80 | CHRM1 (0.49) | CHRM1CHRM4CHRM2ALDH1A1L3MBTL1 | |
| SCHEMBL20585576 | 0.80 | CHRM1 (0.49) | CHRM1CHRM4CHRM2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259802-B2 | Bicyclic aza compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-04-16 | — | — | US | claimed |
| US-20180258085-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-09-13 | — | — | US | claimed |
| US-20170247369-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-08-31 | — | — | US | claimed |
| US-9669013-B2 | Bicyclic aza compounds as muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-06-06 | — | — | US | claimed |
| EP-2897948-B1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2016-08-31 | — | — | EP | claimed |
| US-20160128996-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2016-05-12 | — | — | US | claimed |
| US-9266857-B2 | Bicyclic AZA compounds as muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-23 | — | — | US | claimed |
| US-20150232443-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-08-20 | — | — | US | claimed |
| EP-2897948-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2015-07-29 | — | — | EP | claimed |
| WO-2014045031-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-03-27 | — | — | WO | claimed |
| US-10259802-B2 | Bicyclic aza compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-04-16 | — | — | US | disclosed |
| US-10259802-B2 | Bicyclic aza compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-04-16 | — | — | US | disclosed |
| US-20180258085-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-09-13 | — | — | US | disclosed |
| US-9975890-B2 | Bicyclic AZA compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-05-22 | — | — | US | disclosed |
| US-9975890-B2 | Bicyclic AZA compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-05-22 | — | — | US | disclosed |
| US-20150232443-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20150232443-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| EP-2897948-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014045031-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014045031-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259802-B2 | Bicyclic aza compounds as muscarinic M1 receptor antagonists | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885CHRM4 5/4885CHRM2 2/4885 |
| US-20150232443-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885CHRM4 5/4885CHRM2 2/4885 |
| US-20180258085-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885CHRM4 5/4885CHRM2 2/4885 |
| US-20170247369-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885CHRM4 5/4885CHRM2 2/4885 |
| US-20160128996-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885CHRM4 5/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.